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Abstract
Introduction: The objective of this systematic review and meta-analysis was to determine the effect of renal
replacement therapy (RRT), delivered as hemofiltration vs. hemodialysis, on clinical outcomes in patients with acute
kidney injury (AKI).
Methods: MEDLINE, EMBASE and CENTRAL databases and conference abstracts were searched to June 2012 for
parallel-group or crossover randomized and quasi-randomized controlled trials (RCTs) evaluating hemofiltration vs.
hemodialysis in patients with AKI. Two authors independently selected studies and abstracted data on study
quality and outcomes. Additional information was obtained from trial authors. We pooled data using random-
effects models.
Results: Of 6,657 citations, 19 RCTs (10 parallel-group and 9 crossover) met inclusion criteria. Sixteen trials used
continuous RRT. Study quality was variable. The primary analysis included three parallel-group trials comparing
similar doses of hemofiltration and hemodialysis; sensitivity analyses included trials comparing combined
hemofiltration-hemodialysis or dissimilar doses. We found no effect of hemofiltration on mortality (risk ratio (RR)
0.96, 95% confidence interval (CI) 0.73 to 1.25, P = 0.76; three trials, n = 121 (primary analysis); RR 1.10, 95% CI 0.88
to 1.38, P = 0.38; eight trials, n = 540 (sensitivity analysis)) or other clinical outcomes (RRT dependence in survivors,
vasopressor use, organ dysfunction) compared to hemodialysis. Hemofiltration appeared to shorten time to filter
failure (mean difference (MD) -7 hours, 95% CI (-19,+5), P = 0.24; two trials, n = 50 (primary analysis); MD -5 hours,
95% CI (-10, -1), P = 0.01; three trials, n = 113 (including combined hemofiltration-hemodialysis trials comparing
similar doses); MD -6 hours, 95% CI (-10, -1), P = 0.02; five trials, n = 383 (sensitivity analysis)). Data primarily from
crossover RCTs suggested that hemofiltration increased clearance of medium to larger molecules, including
inflammatory cytokines, compared to hemodialysis, although almost no studies measured changes in serum
concentrations. Meta-analyses were based on very limited data.
Conclusions: Data from small RCTs do not suggest beneficial clinical outcomes from hemofiltration, but
confidence intervals were wide. Hemofiltration may increase clearance of medium to larger molecules. Larger trials
are required to evaluate effects on clinical outcomes.
Introduction
Severe acute kidney injury (AKI) occurs in approxi-
mately 6% of patients admitted to an intensive care unit
(ICU) [1] and in up to 19% of patients with vasopressor-
dependent septic shock [2]. For such individuals, mortal-
ity is approximately 60% [1], and survivors are at
increased risk of requiring permanent renal replacement
therapy (RRT) [3]. Two multicenter randomized con-
trolled trials (RCTs) [4,5] and two meta-analyses [6,7]
have demonstrated that increasing the dose of RRT
above 20 to 25 mL/kg/h of effluent flow for continuous
renal replacement therapy (CRRT) or increasing inter-
mittent dialysis frequency beyond alternate days does
not improve survival.
In addition to dose, the mode of clearance is also a
modifiable component of the RRT prescription that may
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affect patient outcomes. Convective clearance and diffu-
sive clearance, delivered by hemofiltration and hemodia-
lysis, respectively, can be provided by all continuous and
some intermittent RRT machines. Despite similar clear-
ance of small molecules, hemofiltration is reported to
achieve higher clearance of medium-sized to larger
molecules compared to hemodialysis [8]. Consequently,
it is postulated that hemofiltration might benefit criti-
cally ill patients with AKI by better clearing large toxic
inflammatory cytokines [9]. In the absence of a large,
suitably-powered, randomized trial demonstrating the
superiority of one mode over the other, practice surveys
have shown variability in mode selection among coun-
tries and regions [10-15]. Therefore, our objective was
to conduct a systematic review and meta-analysis of all
RCTs comparing the effects of convective clearance
(using hemofiltration) to diffusive clearance (using




We searched OVID versions of MEDLINE, EMBASE
Classic and EMBASE and the Cochrane Central Register
of Controlled Trials (from inception to June 2012) with-
out language restrictions using a previously described
search strategy [6]. We also searched abstracts from criti-
cal care and nephrology professional society conferences,
including: Society of Critical Care Medicine (2004 to
2012), European Society of Intensive Care Medicine
(2001 to 2011), International Symposium of Intensive
Care and Emergency Medicine (2004 to 2012), American
Thoracic Society (2004 to 2012), American College of
Chest Physicians (2003 to 2011), American Society of
Nephrology (2003 to 2011), and the European Renal
Association - European Dialysis and Transplant Associa-
tion (2002 to 2012). We also searched bibliographies of
included studies and personal files. Two reviewers inde-
pendently reviewed all citations and retrieved the full text
of any citation considered potentially relevant by either
reviewer. We attempted to contact selected authors of
included studies for clarification of methods and to
obtain additional data, where required.
Study selection
Two unblinded reviewers assessed full-text reports and
included studies meeting the following criteria: (1)
design: either parallel-group (patients assigned to only
one treatment) or cross-over (each patient received both
treatments in random order) randomized or quasi-ran-
domized (for example, assigning patients in alternating
fashion or by hospital registry number) controlled trial,
(2) population: adult or post-neonatal pediatric patients
with AKI requiring RRT, (3) intervention: hemofiltration
compared to hemodialysis, with both modes applied
using continuous or intermittent RRT; trials comparing
continuous to intermittent RRT were excluded, (4) out-
comes: all-cause mortality (primary outcome) or other
clinically important outcomes (see below) for the paral-
lel-group trials; or group-specific filter duration, or
clearance or plasma concentration measurements of
cleared substances for both parallel-group and crossover
trials. We also included trials of hemodiafiltration (that
is, combined dialysis-filtration) compared to either
hemodialysis or hemofiltration in sensitivity analyses as
explained below.
Data abstraction and validity assessment
Two unblinded reviewers independently abstracted data
from included trials, including study population (number
of centers, age, gender, illness acuity proportion with oli-
guria and sepsis, baseline creatinine and urea), RRT
methods (modality, dose, duration of and criteria for
starting/stopping study RRT), outcomes (mortality, RRT
duration, RRT dependence in survivors, hemodynamics
(for example, vasopressor doses), evolution of organ dys-
function, filter duration, measured clearances and plasma
concentrations of metabolites) and study quality (includ-
ing method of sequence generation and allocation con-
cealment, intention-to-treat analysis, loss to follow-up for
the outcome of mortality, and early trial stopping for effi-
cacy before the planned enrollment was completed). For
the crossover trials we also assessed whether carry-over
effects and washout periods were addressed and whether
paired data analyses were performed [16]. Disagreements
between reviewers regarding study selection and data
abstraction that remained after author contact were
resolved by consensus.
Data analysis
Our primary outcome was all-cause hospital mortality
and, if not available, then mortality at 90, 60, 30 or 28
days after randomization, at ICU discharge or after stop-
ping RRT (in descending order of preference). Secondary
outcomes included RRT dependence among survivors at
the latest time point available (with the same preferred
order of time point as for the mortality analysis), RRT
duration until renal recovery or death, filter duration,
clearance of selected solutes and plasma concentration
measurements.
Binary outcomes are reported as risk ratios (RR) and
continuous outcomes using weighted mean differences
(MD, a measure of absolute change) or ratio of means
(RoM, a measure of relative change) [17]. We used
Review Manager 5.1 (The Cochrane Collaboration,
Oxford, England, UK) to calculate pooled outcome mea-
sures. We considered (two-sided) P <0.05 as statistically
significant and reported individual trial and summary
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results with 95% confidence intervals (CIs). We used ran-
dom-effects models, which incorporate between-trial het-
erogeneity and give wider confidence intervals when
heterogeneity is present, to pool data. We assessed statis-
tical heterogeneity among trials using I2, the percentage
of total variability across studies due to heterogeneity
rather than chance [18,19], and used published thresh-
olds to ascribe low (I2 = 25 to 49%), moderate (I2 = 50 to
74%), and high (I2 ≥75%) heterogeneity [19]. Continuous
variables are expressed as mean ± standard deviation,
unless otherwise indicated. Because the crossover trials
generally did not report within-patient differences, we
used the unpaired group-specific means to pool data,
recognizing that this approach reduces the statistical
power to detect differences [20].
For each outcome, the primary analysis included only
trials in which one group was treated only with hemofil-
tration and the other group only with hemodialysis, with
both groups receiving RRT providing similar (that is,
within 20%) small-molecule clearances. In assessing
equivalency of doses, we determined whether trial
authors adjusted for the reduced dose of hemofiltration
that results from blood dilution by pre-filter replacement
fluid, where applicable. In sensitivity analyses for each
outcome, we included data from trials in which doses dif-
fered by greater than 20% between the convection and
diffusion groups, and from trials comparing combined fil-
tration-dialysis modes to either filtration or dialysis. For
trials in which one group was treated with combined fil-
tration-dialysis, this group was considered either as filtra-
tion (if compared to a dialysis-only group) or dialysis (if
compared to a filtration-only group).
To assess for publication bias we planned to visually
examine a funnel plot of study precision versus treatment
effect on mortality for evidence of asymmetry, assuming
≥5 trials in the analysis.
Because this study reports an analysis of published
data, ethical approval was not required.
Results
Study flow
Our search strategy identified 6,657 citations, 6,324 from
Medline, EMBASE Classic and EMBASE and 333 from
the Cochrane Central Register of Controlled Trials. We
retrieved 41 articles for detailed evaluation, of which 19
studies met criteria for inclusion [21-39] and 22 were
excluded [40-61] (Figure 1). They included 10 parallel-
group trials [21-30] and 9 crossover trials [31-39]. Among
the parallel-group trials, authors of 9 included trials
[21,23-30] provided additional methodological or clinical
data, and the author of the 10th trial [22] informed us that
no additional information was available. In addition,
authors of two studies informed us either that the vast
majority of enrolled randomized patients did not have
renal failure [40], or that it was not a randomized con-
trolled trial [41] (reference [62] is the full paper for the
abstract reference [41]), leading to exclusion of these
studies.
Description of included studies (Table 1)
Enrolled patients had high illness severity. The mean or
median acute physiology and chronic health evaluation
(APACHE) II score [63] was ≥20 or simplified acute
physiology score (SAPS) II [64] was ≥60, as reported in
8 of 10 parallel-group trials [21-27,29] and 3 of 9 cross-
over trials [37-39]. One parallel-group trial reported
only the mean sequential organ failure assessment
(SOFA) [65] score of 16 [30]. Where reported, the vast
majority of patients required mechanical ventilation or
vasopressors [21,23,25,29-32,35,36]. AKI was defined by
abnormal biochemistry (serum creatinine or urea) or a
complication of oliguria (such as volume overload,
hyperkalemia, acidosis or uremic symptoms) in 7 of 10
parallel-group trials [21,23-26,29,30] and 3 of 9 cross-
over trials [34,35,38]. The remaining nine trials enrolled
patients with AKI requiring RRT without reporting spe-
cific AKI criteria [22,27,28,31-33,36,37,39]. Five trials
explicitly excluded patients with chronic kidney disease,
defined by pre-morbid creatinine or creatinine clearance
[23,25,26,29] or recent dialysis [30],
Description of RRT interventions (Table 2)
Seven of the 10 parallel-group trials used continuous
RRT [21,22,24-27,30-39], 1 trial used intermittent RRT
[23] and 2 trials used sustained low efficiency RRT pro-
vided in sessions of eight hours each day [28,29]. Only
three parallel-group trials, all using CRRT, (n = 24 [24], n
= 20 [25], n = 78 [30]) compared exclusively hemofiltra-
tion to exclusively hemodialysis at similar small-molecule
doses. Of these, one trial allocated patients to higher (2.5
L/h) or lower (1 L/h) dose continuous veno-venous
hemofiltration (CVVH) or continuous veno-venous
hemodialysis (CVVHD) in a 2 × 2 factorial design [24]. In
six of the remaining seven parallel-group trials, patients
treated with hemofiltration (n = 20 [21], n = 206 [26], n
= 96 [27]) or hemodialysis (n = 13 [22], n = 39 [23], n =
60 [29]) were compared to a group treated with hemodia-
filtration (hemofiltration and hemodialysis). Hemodiafil-
tration recipients received higher doses, except in three
trials where doses in the two treatment arms were simi-
lar, although not corrected for lower clearance due to
pre-filter addition of replacement fluid [23,27,29]. The
seventh trial, which used sustained low efficiency RRT
and was reported only in abstract form, randomized
patients into three groups: two similar-dose groups of
hemodialysis (n = 6) and hemodiafiltration (n = 5) and a
lower-dose group of hemofiltration (n = 6) [28]. Only
one parallel-group trial was multi-centered [30].
Friedrich et al. Critical Care 2012, 16:R146
http://ccforum.com/content/16/4/R146
Page 3 of 16
All crossover trials were single-centered, used CRRT,
and included few randomized patients (median 11.5
patients (range, 5 to 31)) [31-39]. Six of nine crossover
trials [31,33,34,36-38] compared hemofiltration and
hemodialysis at similar doses. Of these, only three trials
reported post-filter addition of replacement fluid [33,37]
or appropriately adjusted the rate of pre-filter replace-
ment fluid to compare similar clearances [38]. Patients
in one of these three trials [37] received three treat-
ments (post-filter hemofiltration, pre-filter hemofiltra-
tion and hemodialysis) in random order. In another trial
[31], patients received hemofiltration and three doses
of hemodialysis in random order. For this trial, we
excluded the two higher dose hemodialysis groups and
retained the two matched-dose hemofiltration and
hemodialysis groups.
19 RCTs included in meta-analysis 
  10 parallel-group [21-30] 
  9 crossover [31-39] 
 
6657 citations screened for inclusion. 
  6324 from MEDLINE, EMBASE, EMBASE  
 Classic 
  333 from Cochrane Central Registrar of  
 Controlled Trials 
      4 from conference proceedings 
6616 citations excluded   
based on screening 
criteria 
 
41 citations retrieved for detailed evaluation 
22 citations excluded 
   1 – Randomized comparison of 
filtration and dialysis in patients 
without acute renal failure [40]* 
   7 – Non-randomized comparison 
of filtration and dialysis [41-47]  
   8 – RCT of a non-mode 
intervention [48-55] 
   4 – Neither randomized nor 
comparison between filtration and 
dialysis [56-59] 
   2 – Partial duplicate publication 
[60,61] 
 
Figure 1 Flow chart of study selection. *In addition, author contact confirmed that mortality and other clinical outcomes not collected, and
clearance rates not measured for this trial. Abbreviation: RCT, randomized controlled trial.
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20 1 33 45% 28 100% 100%b 646 18 84% h
Alamartine 1994 [22] 13 1 n/r n/r 22 566 30 n/a
Pettila 2001 [23] 39 1 48 82% 20 10 MODS 95% 61%c 446 31 42%
Morgera 2004 [24]
(medians)
24 1 65 58% 31 254 44 50% (ICU)
Daud 2006 [25] (medians) 20 2 50 60% 66 100% 265 19 90% 85% (ICU)
Saudan 2006 [26] 206 1 63 61% 25 9 SOFA 37%d 428 30 60% 53% (90d)
Chang 2009j [27] 96 1 65 57% 31 13 SOFA 238 19 100% 54% (28d)
Ratanarat 2009k [28] 17 1 65 n/c
Ratanarat 2012 [29] 60 1 57 60% 0% 27 93% 67% 449 32 82% 47% (28d)
OMAKI 2012 [30] 77 6 61 61% 16 SOFA 95% 90% 261 22 82% 55%
Crossover
Maher 1988 [31] 5 1 median
51
100% 80% 100%
Alarabi 1992 [32] 13 1 60 62% 38% 92% 100% 453 36
Jeffery 1994 [33] 10 1
Kellum 1998 [34] 13 (10)e 1 100% 77(70) %e
Garcia-Fernandez 2000 [35] 40 1 60 65% 38% 58% 53% 70%i 48% 48%
Maxvold 2000 [36] 6 1 11 33% 17% 100% 50% (
undef)
Wynkel 2004 [37] 18 1 62 39% 60g 50% (30d)
Ricci 2006 [38] (medians) 15 1 50 67% 60% 61
Davies 2008 [39] 45 (31)f 1 61 (57) 64%
(77%)
38% 26
Means, (medians where noted). aHospital mortality except where noted. Oliguria: b<10 mL/h [21], c<500 mL/24h [23], d<200 mL/12 h [26], and i<400 mL/24h [34]. eFor Kellum 1998 [34], 3/13 patients died prior to
being crossed over to other arm. fFor Davies 2008 [39], 45 patients were randomized but only 31 patients crossed over and received both therapies. gWynkel 2004 [37] excluded SAPS II >= 85. hMortality obtained
after author contact [21]. jChang 2009 [27] reported data from 65 patients in abstract form; data for 31 patients who were subsequently randomized provided after author contact. kAuthor informed us that mortality
was not recorded [28]. Abbreviations: APACHE II, acute physiology and chronic health evaluation II [63]; Cr, serum creatinine concentration in micromoles per litre; MODS, multiple organ dysfunction score [66]; n/a,












Table 2 Renal replacement intervention in the included trials
Filtration only group Combined filtration and
dialysis group
Dialysis only group


















Clinician FH77 (Gambro) UFH n/r CAVH (post) 0.9 L/h (median) CAVHDF
(post)














Clinician Polyflux 17 LMWH 250 IHDF (pre) 40 (F) + 128
(D) L/d; 23.5
± 18.8 d
IHD 164 (D) + 4(F) L/
d; 17.5 ± 9.2 d
Morgera
2004 [24]d
Maximum of 3 days Polyflux P2SH 1.1 m2, 10 nm
pore, 50 μm membrane
thickness; 60 kDa cutoff
UFH n/r CVVH (post) 1 or 2.5 L/h; 2.8 d CVVHD 1 or 2.5 L/h; 2.8 d
Daud 2006
[25]
Clinician AN69 0.6 m2, changed daily UFH ≥120 CVVH (pre) 2 L/h; 2.0 (IQR 5.1)
d




Protocol AN69 0.9 m2 (Gambro)
changed daily × 2 d
UFH 100 to
125















CVVH (pre) 2.4k L/h (40 mL/kg/






8.5 ± 8.9 d
Ratanarat
2009 [28]l







39 ± 6l L/d (1.25 ×
















Clinician HF80S (1.8 m2, Kuf 55 mL/h















U/O>500 mL/12h, K <5.5 mM
and HCO3 >18 mM; or
stepdown to IHD when SOFA
CV score <2 for >24h;









3.0.L/h (2.7 L/h post
equiv.) (34 mL/kg/
h); 5 (IQR 3 to 7) d
CVVHD 3.1 L/h (incl. 0.2
L/h F post) (35
mL/kg/h); 4.5 (IQR




n/r FH55 HF or AN69S HD
(Gambro)












Table 2 Renal replacement intervention in the included trials (Continued)
Alarabi
1992 [32]f
24 h Polysulphone (Amicon
AMD30)







0.5 h AN69 Filtral 10 n/r 200 CVVH (post) 1.5 L/h CVVHD 1.5 L/h
Kellum
1998 [34]g
24 h AN69 (0.6 m2) UFH 150 to
200




24 h High Flux polysulfone (0.6
m2) Bellco, Sorin Biomedica
UFH 100 to
150
CVVH (post) 0.71 L/h (median) CVVHDF
(post)








CVVH (pre) 2h L/h CVVHD 2h L/h
Wynkel
2004 [37]






1.5 L/h CVVHD 1.5 L/h
Ricci 2006
[38]
Filter failure AN69 (0.9 m2) multiflow 100,
Hospel, UF coefficient with
blood 25 mL/h/mm Hg ×










35 mL/kg/h (1.45 L/
h pre + 1.5 L/h
post (medians)); 19
(IQR 12.5, 28) h
CVVHD 35 mL/kg/h (2.15
L/h (median)); 37
(IQR 19.5, 72.5) h
Davies
2008 [39]




CVVH (pre) 35 mL/kg/h (mean
3.1 L/h); 8.6 ± 5.6 h
CVVHDF
(pre)
1 D + 0.6 F
L/h; 18.7 ±
3.1 h
aCessation refers to discontinuation of study renal replacement therapy by clinician discretion, or when a fixed time point was reached. For the crossover trials the fixed time point refers to the time prior and after
the crossover (that is, duration of each mode). bFor filtration modes, “pre” and “post” refer to pre- and post-filter infusion of replacement fluid if reported. cFor trials of continuous renal replacement therapy, effluent
flow rates are as reported in the publications assuming no net fluid removal and without adjustment for reduced clearance due to prefilter replacement fluid (for CAVH, CVVH, CAVHDF, or CVVHDF, or IDHF) except
where noted [30]. dFor Morgera 2004 [24], patients were randomized to 1 of 4 groups: 1 or 2.5 L/h of CVVH or 1 or 2.5 L/h of CVVHD. eFor Maher 1988 [31], patients were also randomly crossed over to 2 additional
CAVHD dose groups: 1.5 and 2 L/h of CAVHD. fFor Alarabi 1992 [32], patients were crossed over twice and received three treatments each over 24 hours, either CAVH-CAVHDF-CAVH or CAVHDF-CAVH-CAVHDF. We
only included data from the first two treatments for each patient. gFor Kellum 1998 [34], we only included data from the 10/13 patients that received both treatments (3/13 patients died prior to being crossed over).
hFor the pediatric patients in Maxvold 2000 [36], dose is expressed in L/h/1.73 m2 body surface area. iFor Wynkel 2004 [37], patients were randomly assigned to receive three treatments each over 24 hours in one of
the following orders: CVVHD/CVVHpre/CVVHpost, CVVHpre/CVVHpost/CVVHD, or CVVHpost/CVVHD/CVVHpre. jFor parallel group trials; and for crossover trials that specified duration of RRT based on filter failure and
not a fixed duration of time. kCalculated using mean weight of 59 kg obtained after author contact [27]. lData provided after author contact [28]. Randomized into three groups each treated for 8 hours per day:
dialysis only ("sustained low efficiency daily dialysis” group in published abstract), diafiltration ("sustained low efficiency daily diafiltration” group), and filtration only ("predilution hemofiltration” group). F40s filter
used for the dialysis-only group, and F80s for the diafiltration and filtration-only groups. Blood flow of 200 to 250 mL/min in the dialysis-only and diafiltration groups, and 250 to 300 mL/min in the filtration-only
group. Filtration dose in the filtration-only group (in mL/min) was set at 1.25 × body weight (in kg) and body weight in this group was 64.4 ± 10.2 (mean ± standard deviation).
Abbreviations: CAVH, continuous arteriovenous hemofiltration; CAVHD, continuous arteriovenous hemodialysis; CAVHDF, continuous arteriovenous hemodiafiltration; CV, cardiovascular component of SOFA [65] score;
CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous hemodiafiltration; d, days; equiv., equivalent; D, dialysis dose; F, filtration dose; h, hours;
HCO3, serum bicarbonate concentration; IHD, intermittent hemodialysis; IHDF, intermittent hemodiafiltration; IQR, interquartile range; K, serum potassium concentration; kDa, kiloDalton; kg, body weight in kilograms;
L, liter; LMWH, low molecular weight heparin; μM, micromolar; m2, meter squared; min, minute; mL, milliliter; mM, millimolar; mm Hg, millimeter of mercury; nM, nanomolar; n/r, not reported; post, post-filter addition
of replacement fluid in hemofiltration modes; pre, pre-filter addition of replacement fluid in hemofiltration modes; RRT, renal replacement therapy; SOFA, mean sequential organ failure assessment score [65]; U/O,












In the remaining three crossover trials, hemofiltration
was compared to a mixture of hemofiltration and hemo-
dialysis at either higher [32,35] or lower [39] doses. In
one of these trials [32], patients were crossed over twice
and received their initial treatment a second time; only
data from the first two treatments were included.
One parallel-group trial used different fixed doses
based on weight ranges [26] while two others used
weight-based dosing [27,30]. The parallel-group trials
with sustained low efficiency RRT used fixed doses for
the hemodialysis and hemodiafiltration groups [29] and
weight-based dosing for the hemofiltration group [28].
One crossover trial used weight-based dose prescriptions
for both interventions [38], while another used it only for
hemofiltration [39]. The remaining trials used either
fixed doses [22-25,31,33,34,36,37] or dose ranges not
directly related to patient weight [21,32,35].
Among the parallel-group trials, RRT was discontinued
at the clinicians’ discretion [21-23,25,27,29], after a fixed
duration [24,28], or when protocol-defined criteria were
met [26,30]. The mean duration of RRT ranged from 2 to
8 days in four parallel-group CRRT trials [24,25,27,30]
and just over 20 days in the parallel-group with intermit-
tent therapy [23]. Among the crossover trials, patients
were crossed over after a fixed time: 24 h for most trials
[32,34-37] and 0.5 h for one trial [33]. Two trials crossed
patients over after filter clotting or failure [38,39]. One
trial did not report when patients were crossed over [31].
Study quality (Table 3)
In the parallel-group trials that provided these data, all
patients were analyzed according to the group to which
they were initially assigned, and withdrawal of rando-
mized patients from the mortality analysis either did not
occur [26,27] or comprised ≤5% of randomized patients
[21,23,30]. Caregiver blinding was not practical in any
trial, given the nature of the intervention. Four trials
reported [21,23,26,30] concealed allocation. In three trials
reporting mortality [24,25,27] the authors informed us
that they allocated patients to interventions in an alter-
nating manner. The author of one trial informed us that
the trial stopped early for benefit [26]. This trial was
included only in the sensitivity analyses due to the use of
differing doses and a mixture of hemofiltration and
hemodialysis. Quality measures shown in Table 3 were
generally not reported for the crossover trials, although
in two crossover trials, authors reported that 3/13 (23%)
[34] and 14/45 (31%) [39] patients were not crossed over
to the other treatment. Carryover effects were generally
ignored, which may have been reasonable given that the
impact of clearance mode on solute removal should man-
ifest relatively quickly [8], and subsequent clearance and
concentration measurements were collected over a per-
iod of 12 to 24 hours after crossover in most trials. The
trial with the shortest measurement period (30 minutes)
provided a 10-minute equilibration period after crossover
prior to data collection [33]. For one other trial [37], we
included data collected over 12 hours but not starting
until 12 hours after crossover. Most crossover trials
reported using paired analyses [33-37,39], but none pro-
vided individual patient data or mean within-patient dif-
ference data. Therefore, we were restricted to using
group-specific means to perform meta-analyses, as dis-
cussed in the Methods.
Clinical outcomes
The three parallel group trials that compared similar doses
of hemofiltration to hemodialysis were included in the pri-
mary analysis and reported either ICU [24,25] or hospital
[30] mortality. Five additional parallel-group trials com-
paring similar [23,27,29] or different [21,26] doses of
hemodiafiltration to either hemodialysis or hemofiltration
reported mortality data and were included in the sensitiv-
ity analysis. They reported hospital [21,23], 28-day [27,29],
or 90-day [26] mortality. We did not identify differences in
pooled mortality in the primary (RR 0.96, 95% CI 0.73 to
1.25, P = 0.76; three trials, 121 patients) or sensitivity (RR
1.10, 95% CI 0.88 to 1.38, P = 0.38; eight trials, 540
patients) analyses (Figure 2). Statistical heterogeneity was
absent (I2 = 0%) and moderate (I2 = 50%), respectively.
Visual inspection of the funnel plot for the sensitivity ana-
lysis did not suggest publication bias.
Dialysis dependence in survivors was not different
between groups (primary analysis: RR 1.33, 95% CI 0.35
to 5.08, P = 0.67; two trials [25,30], 37 surviving
patients; sensitivity analysis: RR 0.95, 95% CI 0.44 to
2.04, P = 0.89; four trials [25-27,30], 177 surviving
patients), with no statistical heterogeneity (I2 = 0%).
Two trials reported no differences in SOFA scores 72
hours after starting therapy (primary analysis: RoM 1.02,
95% CI 0.89 to 1.16, P = 0.79; one trial, 63 patients [30];
sensitivity analysis: RoM 1.00, 95% CI 0.61 to 1.64, P =
0.99; two trials, 124 patients [27,30]). One trial reported
lower SOFA scores in the hemofiltration group primar-
ily between four and seven days, driven primarily by the
cardiovascular component (reflecting lower vasopressor
requirements); however, this decrease was not statisti-
cally significant [30]. Another trial reported no differ-
ence in norepinephrine doses or changes in the multi-
organ dysfunction score (MODS) [66] or APACHE II
score between continuous hemofiltration and hemodia-
lysis groups over the first 72 hours [24]. One parallel-
group trial, comparing intermittent hemodiafiltration to
hemodialysis, reported similar improvements in MODS
between groups over 10 days [23], and another compar-
ing sustained low efficiency dialysis to diafiltration
reported similar improvements in blood pressure
between groups over three days [29].
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Table 3 Risk of bias of included trials
Trial Sequence
generation




Post-randomization withdrawals for mortality analysis (parallel






Yesa No Yes Yes - 1/12 CVVHD(lost to follow up)
Alamartine 1994
[22]a
n/r n/r n/r n/r n/r
Pettila 2001 [23] Computer
generated
Yesa (closed envelopes) No Yes Yes - 1/18 IHD(consent withdrawn)
Morgera 2004 [24] Alternating
patientsa
No No Yes n/r
Daud 2006 [25] Alternating
patientsa
No No Yes n/r
Saudan 2006 [26] Computer
generated
Yes (sequentially numbered sealed
opaque envelopes)
Yesa Yes No
Chang 2009 [27] Alternating
patientsa










n/r n/r n/r n/r
OMAKI 2012 [30] Computer
generated
Yes (sequentially numbered sealed
opaque envelopes)
No Yes Yes - 1/39 CVVHD(inclusion mistake)
Crossover
Maher 1988 [31] n/r n/r n/r n/r n/r
Alarabi 1992 [32] n/r n/r n/r n/r n/r
Jeffery 1994 [33] n/r n/r n/r n/r n/r
Kellum 1998 [34] n/r n/r n/r n/r Yes - 2 CVVH and 1 CVVHD/13 died prior to crossover
Garcia-Fernandez
2000 [35]
n/r n/r No n/r n/r
Maxvold 2000 [36] n/r n/r n/r n/r n/r
Wynkel 2004 [37] n/r n/r n/r n/r n/r
Ricci 2006 [38] n/r n/r n/r n/r n/r
Davies 2008 [39] n/r n/r n/r n/r Yes - 14/45 not crossed over












Pooled data from two small crossover trials using similar
dose CVVH vs. CVVHD [34,38] suggest that hemofiltra-
tion may shorten the time to filter failure, although only
the RoM result achieved statistical significance (MD -7.3
hours, 95% CI -19.4 to +4.9, P = 0.24, I2 = 38%; RoM 0.67,
95% CI 0.45 to 0.99, P = 0.04, I2 = 7%; n = 50). Incorporat-
ing the results of one parallel-group trial using similar
dose CVVH vs. hemodiafiltration (CVVHDF) [27] pro-
duced a pooled result that was significant for both effect
measures (MD -5.4 hours, 95% CI -9.6 to -1.3 hours, P =
0.01; RoM 0.70, 95% CI 0.56 to 0.88, P = 0.003; I2 = 0% in
both analyses; n = 113). Recognizing that higher dose may
also affect filter life, two other trials comparing non-
equivalent doses in the two treatment arms demonstrated
shorter time to filter clotting in the higher dose group.
One crossover trial comparing higher dose CVVH to
CVVHDF [39] demonstrated an even greater decrease in
filter life in the CVVH group, and one parallel group trial
comparing lower dose CVVH to CVVHDF [26] demon-
strated a non-statistically significant shorter time to filter
clotting in the higher-dose group (Figure 3). Including the
data from trials with non-equivalent doses in the two
treatment arms in the pooled analysis resulted in a similar
shortened time to filter failure in the hemofiltration group
(MD -5.6 hours, 95% CI -10.4 to -0.9 hours, P = 0.02;
RoM 0.69, 95% CI 0.50 to 0.95, P = 0.02; five trials, 383
patients), with higher heterogeneity (I2 = 51 to 66%). All
these trials used unfractionated heparin anti-coagulation
and pre-filter replacement fluid except for one trial that
used a mixture of pre- and post-filter replacement to keep
the filtration fraction <20% [38]. This reduction in filter
survival time of about one-third is equivalent to a 50%
increase in filters required for hemofiltration compared to
hemodialysis.
Figure 2 Effect of hemofiltration vs. hemodialysis RRT on mortality. The pooled risk ratio was calculated using a random-effects model.
Weight refers to the contribution of each study to the overall estimate of treatment effect. Abbreviations: CI, confidence interval; IV, inverse
variance.
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Clearances of small and large molecules (Table 4)
Few molecules were examined in more than one study,
and analyses included few patients. In general, small
molecule clearance (for example, urea, phosphate and
creatinine) was similar between hemofiltration and
hemodialysis, whereas hemofiltration achieved higher
clearance of larger molecules (up to around 20 kiloDal-
tons (kDa)). Pooled data from two studies [24,34]
showed similar clearance of interleukin (IL)-6 between
modes, but statistical heterogeneity was high. Single stu-
dies also found that hemofiltration delivered significantly
higher clearances of protein and albumin (using a high
(60 kDa) cut-off filter) [24], and almost all amino acids
in one study examining pediatric patients receiving
amino acid supplementation [36].
The impact of clearance mode on serum concentra-
tions of various solutes of interest was reported even
less frequently. One crossover trial [34] found the con-
centration of tumor necrosis factor (TNF) a (but not
IL-6, IL-10, SL-selectin, and endotoxin) to be signifi-
cantly lower in the patients during hemofiltration. A
second crossover trial [35] found no differences in con-
centrations of mediators of endothelial activation. One
parallel-group trial [25] measured a larger decrease in
IL-6 and smaller increase in TNFa concentration in the
hemofiltration group, but these cytokines were only
measured in one patient treated with hemofiltration and
two patients treated with hemodialysis. Finally, the
crossover trial of pediatric patients receiving amino acid
supplementation [36] reported lower serum concentra-
tions of amino acids in association with higher clear-
ances in the hemofiltration group.
Discussion
This systematic review and meta-analysis highlights the
paucity of data from randomized controlled trials com-
paring hemofiltration to hemodialysis in the treatment
of AKI. Considering clinical outcomes of hemofiltration
in parallel-group RCTs, there was no indication of
improved mortality or organ dysfunction, although con-
fidence intervals were wide. Our meta-analysis suggests
that hemofiltration shortens filter life by about five to
six hours (or one-third of total mean filter time). Based
primarily on crossover RCTs, we found that hemofiltra-
tion increases the clearance of medium to larger mole-
cules compared to hemodialysis. Almost no studies
determined whether the enhanced middle-molecule
clearance attributed to hemofiltration actually led to
lower serum concentrations.
The trials reporting on filter failure rates used primar-
ily pre-filter addition of replacement fluid. Comparing
pre-filter to post-filter addition, one trial [37] included
in this meta-analysis and other studies [67-69] have
demonstrated that replacement fluid requirements are
Figure 3 Effect of hemofiltration vs. hemodialysis on filter life. The pooled mean difference was calculated using a random-effects model.
Weight refers to the contribution of each study to the overall estimate of treatment effect.
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about 15 to 20% higher to achieve similar small mole-
cule clearance rates at doses of around 20 mL/kg/h. Our
finding of a 33% shorter time to filter failure with hemo-
filtration, combined with its higher fluid requirements to
achieve similar small molecule clearance, implies that
hemofiltration may consume more resources than
hemodialysis. This hypothesis merits further evaluation
in a formal cost analysis.
Comparing the published practice survey data in differ-
ent countries and regions [10-15] (summarized in Figure
4), it appears that physicians tend to use a mode with at
least some hemofiltration (that is, either CVVH or
CVVHDF), perhaps anticipating additional benefit asso-
ciated with hemofiltration. However, the small number of
trials, randomized patients and events does not support
this belief. A well-designed and adequately powered trial
would be necessary to establish the superiority of
hemofiltration.
Strengths of our review include methods to minimize
bias, such as a comprehensive literature search, duplicate
data abstraction, consideration of important clinical out-
comes, and inclusion of additional methodological or clini-
cal information from authors. The primary limitation is
the small number and size of RCTs comparing pure
hemofiltration to pure hemodialysis at similar doses. Sen-
sitivity analyses, including trials whose arms also varied
with respect to dose, gave similar results, as expected
given recent large trials [4,5] and meta-analyses [6,7] that
found similar outcomes with different RRT doses. In addi-
tion, trials varied in the modality of RRT used, timing of
initiation, and types of filters and blood flows, although
recent meta-analyses have not found differential outcomes
based on these factors [70-73]. We did not consider com-
parisons of blood clearance modes with peritoneal dialysis
[74,75], which is used in some areas of the world to treat
acute kidney failure. Finally, heterogeneity may have been
underestimated because these tests are underpowered
when there are few trials. Although hemofiltration is of
particular interest in patients with sepsis, in whom pro-
inflammatory mediators are increased, there was insuffi-
cient data to conduct a subgroup analysis in these patients.
In addition, we did not examine the role of hemofiltration
vs hemodialysis in patients with sepsis who have not yet
developed AKI [40] or the role of hemofiltration compared
to no RRT [76-79].
Conclusions
Pooled data from a few randomized trials suggest that
hemofiltration increases the clearance of medium to lar-
ger molecules without improving clinical outcomes,
though confidence intervals are wide. Hemofiltration
may also reduce filter life. This latter finding, together
Table 4 Clearance measurements of hemofiltration vs.
Change in clearance hemofiltration vs hemodialysisa











Urea (60 Da) 4 [33,36-38]; 49 +1%b -2% to +3% 0.60 0%
Phosphate (95 Da) 1 [37]; 18 0%c -4% to +4% 1.00 n/a
Creatinine (113 Da) 3 [33,37,38]; 43 +1.8%b -0.4% to +4.1% 0.12 0%
Uric acid (168 Da) 2 [33,37]; 28 +4% +1% to +7% 0.01 0%
Larger molecules
Vancomycin (1.8 kDa) 1 [33]; 10 +18% +8% to +28% 0.0003 n/a
b2-microglobulin (11.8 kDa) 2 [37,38]; 33 +94%
d +78% to +112% <0.0001 0%
IL-1 Receptor Agonist (16-18
kDa)
1 [24]; 12 +77%e,f +24% to +153% 0.002 n/a
Retinol Binding Protein (21.2
kDa)
1 [37]; 18 +42% +4% to +94% 0.03 n/a
IL-6 (26 kDa) 2 [24,34]; 22 +6%f,g -62% to +191% 0.91 89%
hemodialysis
aUsing RoM. bResults are unchanged if two trials either using different ultrafiltration rates [31] or comparing different doses of hemofiltration vs a mixture of
hemodialysis and hemofiltration [21] are also included after accounting for the different flow rates (urea clearance +1% (95% CI -2% to +3%, P = 0.58, I2 = 0%,
six studies [21,31,33,36-38], 74 patients) and creatinine clearance +1.9% [95% CI -0.3% to +4.1%, P = 0.09, I2 = 0%, five studies [21,31,33,37,38], 68 patients)).
cResults unchanged if data from the filtration-only vs dialysis-only groups in the sustained low efficiency RRT trial [28] are added: +31% (95% CI -35% to +165%,
P = 0.45, I2 = 72%, two studies [28,37], 30 patients). dOne of these studies [38] also measured adsorptive clearance of b2-microglobulin and found negligible
(<1%) clearance occurred via adsorption to the filter and this was similar between hemofiltration and hemodialysis. eComparing higher-dose (2.5 L/h) groups
only. Comparing lower-dose (1 L/h) groups in the same study [24] showed a smaller but still statistically significant increased clearance of IL-1 Receptor Agonist
+28% (95% CI +10% to +50%%, P = 0.002). fThe medians and ranges reported in this trial [24] were converted to means and standard deviations using published
guidelines [81]. gIncluding the higher-dose (2.5 L/h) groups for Morgera 2004 [24] only. Including also the lower-dose (1 L/h) groups for this trial [24] produced
similar results -2% (95% CI -46% to +80%%, P = 0.96, I2 = 0%, two studies [24,34], 34 patients]. Abbreviations: CI, confidence interval; Da, Daltons; I2, I2
heterogeneity measure; IL, interleukin; kDa, kiloDaltons; n/a, not applicable; RoM, ratio of means [17]; RRT, renal replacement therapy.
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with the increased replacement fluid requirements to
achieve equivalent small-molecule clearance when pre-
filter replacement is used, suggests that hemofiltration
may be more expensive than hemodialysis. Our findings
support the need for additional pilot data [80] to evalu-
ate the impact of hemofiltration vs. hemodialysis on
intermediate outcomes, such as vasopressor require-
ments, that may serve as valid surrogates for important
clinical outcomes that could subsequently be evaluated
in a large definitive trial.
Key messages
• Few randomized controlled trials have compared
hemofiltration vs hemodialysis for the treatment of
acute kidney injury.
• Pooling the results from these trials does not sug-
gest beneficial clinical outcomes of hemofiltration vs
hemodialysis, but confidence intervals are wide.
• Compared to hemodialysis, hemofiltration may
increase clearance of medium to larger molecules,
but may also shorten the time to filter failure.
• Additional pilot trials are needed to evaluate the
impact of hemofiltration vs. hemodialysis on inter-
mediate outcomes, such as vasopressor require-
ments, that may serve as valid surrogates for
important clinical outcomes that could subsequently
be evaluated in a large definitive trial.
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